Dorothy Keefe1, Jude Lees, Noemi Horvath. 1. Department of Medical Oncology, Royal Adelaide Hospital Cancer Centre, Adelaide, South Australia.
Abstract
GOALS OF WORK: the aim of this paper was to review the initial use of Palifermin(rHu-KGF1) in a single institution, for the prevention of oral mucositis in high-dose chemotherapy and stem cell transplantation. METHODS: the case records of the first five patients treated with Palifermin at the Royal Adelaide Hospital Cancer Centre were reviewed, and incidence,severity and duration of the oral mucositis were recorded, as well as demographics and toxicities. RESULTS: two of the five patients developed grade 4 mucositis, and the remaining three patients developed grade 2 mucositis. Palifemin was well tolerated with only one patient developing a rash. CONCLUSIONS: the severity of oral mucositis was less than would be expected in these patients without anti-mucositis therapy. Palifermin was well tolerated. Obviously this single institution report is from a very small cohort of patients, but it is encouraging for the ease of use of this drug in the future.
GOALS OF WORK: the aim of this paper was to review the initial use of Palifermin(rHu-KGF1) in a single institution, for the prevention of oral mucositis in high-dose chemotherapy and stem cell transplantation. METHODS: the case records of the first five patients treated with Palifermin at the Royal Adelaide Hospital Cancer Centre were reviewed, and incidence,severity and duration of the oral mucositis were recorded, as well as demographics and toxicities. RESULTS: two of the five patients developed grade 4 mucositis, and the remaining three patients developed grade 2 mucositis. Palifemin was well tolerated with only one patient developing a rash. CONCLUSIONS: the severity of oral mucositis was less than would be expected in these patients without anti-mucositis therapy. Palifermin was well tolerated. Obviously this single institution report is from a very small cohort of patients, but it is encouraging for the ease of use of this drug in the future.
Authors: S A Aaronson; D P Bottaro; T Miki; D Ron; P W Finch; T P Fleming; J Ahn; W G Taylor; J S Rubin Journal: Ann N Y Acad Sci Date: 1991 Impact factor: 5.691
Authors: Ricardo Spielberger; Patrick Stiff; William Bensinger; Teresa Gentile; Daniel Weisdorf; Tarun Kewalramani; Thomas Shea; Saul Yanovich; Keith Hansen; Stephen Noga; John McCarty; C Frederick LeMaistre; Eric C Sung; Bruce R Blazar; Dieter Elhardt; Mon-Gy Chen; Christos Emmanouilides Journal: N Engl J Med Date: 2004-12-16 Impact factor: 91.245
Authors: C L Farrell; J V Bready; K L Rex; J N Chen; C R DiPalma; K L Whitcomb; S Yin; D C Hill; B Wiemann; C O Starnes; A M Havill; Z N Lu; S L Aukerman; G F Pierce; A Thomason; C S Potten; T R Ulich; D L Lacey Journal: Cancer Res Date: 1998-03-01 Impact factor: 12.701
Authors: Stephen T Sonis; Linda S Elting; Dorothy Keefe; Douglas E Peterson; Mark Schubert; Martin Hauer-Jensen; B Nebiyou Bekele; Judith Raber-Durlacher; J Peter Donnelly; Edward B Rubenstein Journal: Cancer Date: 2004-05-01 Impact factor: 6.860
Authors: Diana T Nguyen; Sepideh Shayani; Joycelynne Palmer; Andrew Dagis; Stephen J Forman; Joel Epstein; Ricardo Spielberger Journal: Support Care Cancer Date: 2015-03-21 Impact factor: 3.603
Authors: Judith E Raber-Durlacher; Inger von Bültzingslöwen; Richard M Logan; Joanne Bowen; Abdul Rahman Al-Azri; Hele Everaus; Erich Gerber; Jesùs Garcia Gomez; Bo G Pettersson; Yoshihiko Soga; Fred K L Spijkervet; Wim J E Tissing; Joel B Epstein; Sharon Elad; Rajesh V Lalla Journal: Support Care Cancer Date: 2012-09-18 Impact factor: 3.603
Authors: Richard M Logan; Abdul Rahman Al-Azri; Paolo Bossi; Andrea M Stringer; Jamie K Joy; Yoshihiko Soga; Vinisha Ranna; Anusha Vaddi; Judith E Raber-Durlacher; Rajesh V Lalla; Karis Kin Fong Cheng; Sharon Elad Journal: Support Care Cancer Date: 2020-02-21 Impact factor: 3.603